Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non ‐small cell lung cancer

ConclusionsWith the sequential ALK inhibitors treatment, cancer cells accumulate new mutations in addition to mutations acquired previously. The identified compound mutation (I1171S  + G1269A) was found to be sensitive to ceritinib and brigatinib, and indeed the patient's tumor partially responded to ceritinib.Key points
ALK compound mutation was found in a clinical sample that was resistant to lorlatinib after sequential ALK ‐tyrosine kinase inhibitor (TKI) treatment.
Ceritinib and brigatinib are potential overcoming drugs against ALK I1171S + G1269A double mutation.

Source: Thoracic Cancer - January 12, 2020 Category: Cancer & Oncology Authors: Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh ‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama Tags: ORIGINAL ARTICLE Source Type: research